Drugs / Ad5-nCoV-IH
Ad5-nCoV-IH
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05330871 | Apr → Jun 2022 | COVID-19 | Seventh Medical Center of PLA General Hospital | Unknown | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT05517642 | Sep 2022 → May 2023 | COVID-19 | CanSino Biologics Inc. | Completed | Missed primary |
| Phase 3 | NCT05169008 | Feb 2022 → Jan 2023 | COVID-19 | CanSino Biologics Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05124561 | Dec 2021 → Apr 2022 | COVID-19 | CanSino Biologics Inc. | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2023-03-02 | CanSino Biologics Inc. | Regulatory CanSinoBIO's Convidecia Air® Receives Approval in Indonesia cansinotech.com ↗
Tianjin, March 1, 2023 – CanSino Biologics Inc. (“CanSinoBIO” or “the Company”) (SSE: 688185, HKEX: 06185) today announced that the Badan Pengawas Obat dan Makanan (“BPOM”) has granted the Company Emergency Use Approval for its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation Convidecia Air® as a heterologous booster. |
| 2022-11-10 | CanSino Biologics Inc. | Regulatory CanSinoBIO’s Convidecia Air™ Approved for Emergency Use in Morocco cansinotech.com ↗
Convidecia Air™, utilizing Aerogen’s proprietary aerosol drug delivery technology, has so far been approved for emergency use in China and Morocco. |
| 2022-10-25 | CanSino Biologics Inc. | Regulatory CanSino Biologics Celebrates the Rollout of the Inhaled Vaccine, Convidecia Air™, in Shanghai cansinotech.com ↗
its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (trade name: Convidecia Air™) has been approved by the Joint Prevention and Control Mechanism of the State Council of China for inclusion in Shanghai’s booster vaccination program |
| 2022-10-06 | CanSino Biologics Inc. | Results CanSinoBIO to Present Latest Data on Convidecia Air™ at the World Vaccine Congress Europe 2022 cansinotech.com ↗
These data will show that Convidecia Air™ induces a strong and lasting immune response[1], with greater immunogenicity against the Omicron variant than recombinant protein or inactivated vaccines. |
| 2022-09-04 | CanSino Biologics Inc. | Regulatory CanSinoBIO's Convidecia Air™ Receives Approval in China cansinotech.com ↗
announced that the National Medical Products Administration of China (“NMPA”) has granted the Company approval for its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation |
| 2022-08-18 | CanSino Biologics Inc. | Regulatory Convidecia Air™ Receives Clinical Trial Approval in Malaysia cansinotech.com ↗
CanSino Biologics Inc. (“CanSinoBIO”) (SSE: 688185, HKEX: 06185) today announced that its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (trade name: Convidecia Air™) has received approval for clinical trial in Malaysia, marking the first trial study of the inhaled version of COVID-19 vaccine in Malaysia. |
| 2022-03-14 | CanSino Biologics Inc. | Results Latest Study Shows Advantages of CanSinoBIO’s Convidecia as Heterologous Booster against Omicron Variant cansinotech.com ↗
The results showed that booster vaccination with either intramuscular injection or inhaled version of Convidecia generated greater neutralizing antibody responses than those induced by the homologous inactivated vaccine booster or heterologous recombinant protein vaccine booster. |
| 2022-01-11 | CanSino Biologics Inc. | Results Latest Study Shows Encouraging Results of CanSinoBIO’s Inhaled COVID-19 Vaccine as Heterologous Booster cansinotech.com ↗
The study showed that boosting the inactivated vaccine with the Inhalation Convidecia™stimulates a strong mucosal immune response. |
| 2021-09-06 | CanSino Biologics Inc. | Results Coronavirus Pandemic: Chinese developer shares efficacy of inhaled vaccines cansinotech.com ↗
They've said that the first phase of clinical trials has shown promising results. |
All press releases naming this drug 14 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5-nCoV-IH | “Ad5-nCoV-IH, 1 dose 0.1ml” NCT05330871 ↗ |
| Known as | AAd5 | “Heterologous booster immunisation with orally administered aerosolised Ad5-nCoV vaccine (AAd5) has been shown to be safe and highly immunogenic in adults.” PMID 37209700 ↗ May 2023 |
| Known as | Convidecia | “receive a second booster dose of IH Convidecia vaccine (treatment arm)” NCT05517642 ↗ |
| Known as | IH Convidecia | “receive a second booster dose of IH Convidecia vaccine (treatment arm)” NCT05517642 ↗ |
| Known as | Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH) | “Biological: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)” NCT05169008 ↗ |
| Modality | Vaccine | “Recombinant COVID-19 vaccine” NCT05124561 ↗ |
| Route | Inhaled | “Nebulized inhalation through the mouth” NCT05124561 ↗ |